期刊
BIOMOLECULES
卷 9, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/biom9110734
关键词
Alzheimer's disease; prodromal; prognosis; microRNA; microfluidic device
资金
- Health Research Board [HRA-POR-2015-1243]
- Science Foundation Ireland [12/COEN/18, 17/CDA/4708, 18/FIP/3552]
- Science Foundation Ireland (European Regional Development Fund) [16/RC/3948]
- Science Foundation Ireland (FutureNeuro industry partners) [16/RC/3948]
- CIBERNED
- Spanish Ministry of Science [SAF2016-78603-R]
- Queen Sofia Foundation
- CIEN Foundation
- Carlos III Institute of Health
- Science Foundation Ireland (SFI) [18/FIP/3552, 12/COEN/18] Funding Source: Science Foundation Ireland (SFI)
The need for practical biomarkers for early diagnosis of Alzheimer's disease (AD) remains largely unmet. Here we investigated the use of blood-based microRNAs as prognostic biomarkers for AD and their application in a novel electrochemical microfluidic device for microRNA detection. MicroRNA transcriptome was profiled in plasma from patients with mild cognitive impairment (MCI) and AD. MicroRNAs Let-7b and microRNA-206 were validated at elevated levels in MCI and AD, respectively. MicroRNA-206 displayed a strong correlation with cognitive decline and memory deficits. Longitudinal follow-ups over five years identified microRNA-206 increases preceding the onset of dementia. MicroRNA-206 was increased in unprocessed plasma of AD and MCI subjects, detected by our microfluidic device. While increased Let-7b levels in plasma may be used to identify patients with MCI, changes in plasma levels of microRNA-206 may be used to predict cognitive decline and progression towards dementia at an MCI stage. MicroRNA quantification via a microfluidic device could provide a practical cost-effective tool for the stratification of patients with MCI according to risk of developing AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据